Drug discovery

ulcerative colitis
#AI #BenevolentAI #Drug discovery #Ulcerative colitis (UC)

First patients dosed with an AI-derived target for ulcerative colitis 

BenevolentAI has dosed the first patients in Phase I first-in-human studies of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8744, intended for the treatment of ulcerative colitis (UC). The topline data readout from this study is expected in the first quarter of 2024.  UC is a chronic disease… Read More

#News

eBook
#Biosensors #Drug discovery #eBook #Interaction analysis #Molecular research #Pharmokinetics

Binding kinetics in hours instead of days – download the eBook

A new eBook is now available from Malvern Panalytical: ‘Faster, more accurate and deeper insight: How to make the switch to label-free interaction analysis.’ Label-free interaction analysis takes discovery to a new level. It removes inaccuracies and inefficiencies, but it also uncovers a new layer of insight… Read More

#News

#Biosensors #Drug discovery #Interaction analysis #Molecular research #Pharmokinetics

Binding kinetics in hours instead of days with label-free interaction analysis

Label-free interaction analysis takes discovery to a new level. It removes inaccuracies and inefficiencies, but it also uncovers a new layer of insight into the kinetic activity and binding specificity of a greater range of analytes. GCI technology brings you closer to your analytes, allowing you to see interactions in… Read More

#Resources

New appointments
#Appointment #Drug discovery #New appointment

Drug discovery’s latest top-level appointments

It’s not unusual for such a dynamic industry to have regular shake-ups in senior leadership, especially as innovative new technologies create brand new roles. The last couple of months have seen a number of high-profile job moves in drug discovery. Dr Robert Kirby, COO and Dr Edward Stevens,… Read More

#Business & Investment #News

#BioInnovation Institute #Drug discovery #Funding #Investment #Start-ups

Three therapeutics start-ups join acceleration programme

The BioInnovation Institute (BII) has welcomed three new drug discovery start-ups into its Venture Lab acceleration programme as part of its latest cohort of eight companies. The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific and team development, and provides… Read More

#News #Start-up Zone

Danaher Corporation
#Abcam #Danaher Corporation #Drug discovery #Mergers and acquisitions

Danaher to acquire Abcam

The two companies have entered an agreement in which Danaher Corporation will acquire Abcam for $24 per share in cash. The transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. Founded… Read More

#Business & Investment #News

#ADME / Tox #Drug development #Drug discovery #Regulatory #Webinar

Register now: Why are ADME and DDI investigations important?

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place… Read More

Webinar date:
Supported by BioIVT
#News

Medical research
#ADME / Tox #Drug development #Drug discovery #Regulatory #Webinar

ADME and DDI considerations during drug development

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place… Read More

Webinar date:
Supported by BioIVT
#News

#Drug development #Drug discovery #Generics #Regulatory

Pioneering access to complex generic products 

Claire D’Abreu-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines.   Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. This will continue to be the case going forward,… Read More

#Exclusive Content

Medical researcher
#ADME / Tox #Drug development #Drug discovery #Regulatory #Webinar

ADME and DDI considerations during drug development

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place… Read More

Webinar date:
Supported by BioIVT
#News

Lab mouse
#Animal models #Drug discovery #Mouse models #Taconic

More efficient mouse model generation through informed founder selection

This paid-for advertorial by Taconic appeared in DDW Volume 24 – Issue 3, Summer 2023 Overcoming challenges in model generation Genetically engineered mouse models are essential tools for biomedical research. Yet when seeking to obtain an existing model, researchers often encounter obstacles related to intellectual property, availability, or licensing. Read More

#Exclusive Content

Medical research
#ADME / Tox #Drug development #Drug discovery #Regulatory #Webinar

Learn about ADME and DDI considerations in drug discovery

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place… Read More

Webinar date:
Supported by BioIVT
#News

Medical research
#ADME / Tox #Drug development #Drug discovery #Regulatory

Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application?

In vitro ADME and drug-drug interaction (DDI) investigations are early activities in the drug development process that are critical for framing downstream decision making. Understanding the ADME properties and DDI risks of your compound helps you avoid unnecessary clinical studies, costs, delays and more. This webinar will provide insights at… Read More

Webinar date:
Supported by BioIVT
#Webinars